Details for Patent: 6,410,511

Summary for Patent: 6,410,511

Title:	Formulations for amylin agonist peptides
Abstract:	The present invention is concerned with a pharmaceutical formulation in a container, for example, a vial, prefilled cartridge, prefilled syringe or disposable pen, comprising approximately 0.01 to about 0.5% (w/v) amylin agonist, preferably pramlintide, in an aqueous system along with approximately 0.02 to about 0.5% (w/v) of an acetate, phosphate, citrate, or glutamate buffer to a pH of the final composition of approximately 3.0 to about 6.0 as well as approximately 1.0 to 10% (w/v) of a carbohydrate or polyhydric alcohol tonicifier; and, optionally, approximately 0.005 to 1.0% (w/v) of a preservative selected from the group consisting of m-cresol, benzyl alcohol, parabens and phenol. These formulations maintain stability upon storage under refrigerated or room temperature conditions. Such formulations can be further combined with insulin in the same syringe for administration to a patient.
Inventor(s):	L'Italien; James (Del Mar, CA), Musunuri; Shankar (Exton, PA), Ruby; Kale (San Diego, CA)
Assignee:	Amylin Pharmaceuticals, Inc. (San Diego, CA)
Application Number:	09/005,262
Patent Claim Types: see list of patent claims	Formulation; Compound; Composition; Use; Dosage form;

Drugs Protected by US Patent 6,410,511

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 6,410,511

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2003238862
Canada	2487585
European Patent Office	1551436